Compare Mesoblast Limited (MESO) vs United States Natural Gas Fund (UNG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Mesoblast Limited vs United States Natural Gas Fund — how do they compare? Mesoblast Limited trades at $16.83 (market cap $2.21B), while United States Natural Gas Fund trades at $10.22. The key difference: Mesoblast Limited is trading nearer its 52-week high, United States Natural Gas Fund nearer its low. Which is the better fit depends on your goals.
| MESO | UNG | |
|---|---|---|
Market Cap | $2.21B | — |
Sector | Technology | Commodities - Energy |
52-Week High | $20.96 | $16.90 |
52-Week Low | $12.88 | $9.63 |
Enterprise Value | $2.21B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MESO trades at $16.9, up 1.32% on the day, with a bullish technical signal from moving averages. The company reported Ryoncil net revenues of $36 million for the quarter ended June 30, 2026, and achieved its target of 300 patients in a Phase 3 trial for chronic low back pain. Despite strong revenue growth from its commercial launch, fundamentals show a net income margin of -144.33% and negative EBITDA of $80.06 million for 2025, reflecting significant losses amid expansion.
The outlook hinges on commercial execution and regulatory progress, with analyst consensus leaning buy (45% buy ratings). Key risks include high cash burn, dependence on pipeline success, and competitive pressures. Upside potential exists if revenue growth accelerates and losses narrow, but investors face volatility from clinical trial outcomes and funding needs.
UNG, the United States Natural Gas Fund, trades at $10.23, up 0.89% on the day, with technical indicators showing a bearish bias from moving averages but neutral oscillators. The fund tracks natural gas futures, with recent news highlighting steady prices amid weather-driven demand shifts and geopolitical tensions affecting commodity markets. Key support and resistance cluster around $10, indicating a critical price zone.
The outlook for UNG hinges on natural gas supply-demand dynamics, with EIA forecasting record highs in 2026, but risks include volatility from weather patterns and Middle East conflicts. Investment appeal lies in exposure to energy themes, though the fund's structure as a futures tracker may lead to divergence from spot prices, as noted in comparative analyses with equity-based ETFs like FCG.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →About United States Natural Gas Fund
UNG is a commodity ETF that tracks the daily price movements of natural gas futures. It primarily invests in front-month contracts at the Henry Hub, making it a highly volatile tool for short-term trading rather than long-term holding due to contango and roll costs.
Read more on UNG →
